CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Diagnosed with relapsed or refractory AML (cancer that came back or didn't respond to treatment) with a specific marker called NKG2D ligand
- Bone marrow showing at least 5% blast cells (immature blood cells)
- Expected to live at least 12 more weeks
- Good heart, liver, kidney, and blood-clotting function without needing ongoing support
- No previous CAR-T therapy, stem cell transplant in the past 3 months, or active uncontrolled infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, CT1390B, for people whose acute myeloid leukemia (AML) has come back or not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
This trial tests a new treatment called CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatments. CAR-T cells are specially designed to find and destroy cancer cells. The goal is to see if this therapy is safe and works for patients whose cancer cells have specific markers (CD33, CD123, or CLL-1).
This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.